Biotech | February 28, 2022
BDR Pharma launches enzalutamide in 160 mg strength
This medicine was previously available in 40mg and 80mg strength, for which patients had to consume 2 tablets a day as per the approved dosage
This medicine was previously available in 40mg and 80mg strength, for which patients had to consume 2 tablets a day as per the approved dosage
In a European work-sharing procedure (WSP), Glucophage was approved as the first oral anti-diabetic medication to be used safely from conception to birth
Collaboration with MTPC to discover novel hit compounds for multiple drug targets
Cantex also plans to initiate Phase 2 clinical trials exploring the therapeutic effect of azeliragon in pancreatic and breast cancers.
Tamper evident caps with incorporated RFID technology offer a significant reduction in RFID implementation costs
Keytruda plus Lenvima is also approved in the U.S. and Europe for the first-line treatment of adult patients with advanced RCC.
Boehringer Ingelheim plans to study this novel investigational therapy in patients with progressive fibrosing interstitial lung diseases
Medicago and GSK collaborated on Covifenz, an adjuvanted plant-based vaccine
UNICOR-v has the potential to protect against future epidemics caused by a coronavirus jumping from animals to humans, but also against new variants emerging from SARS-Cov-2
Fyarro added to NCCN guidelines as the only preferred mTOR inhibitor to treat malignant PEComa
Subscribe To Our Newsletter & Stay Updated
